Reshaping the HIV treatment and prevention landscape
External benchmarks position GSK in the top
quartile for R&D output from 2017-2020
Launches
Number; 2017-20
16
gsk
Launches per $1bn R&D spend
Number / US$B; 2017-20*
Median PYS per Launch Asset**
US $B; timeframe 2017-26
Company 1
1.9
0.7
gsk
10
1.9
1.3
Q1
:
Company 2
10
1.0
0.7
Company 3
9
1.7
1.1
Company 4
9
1.6
0.8
Company 5
8
1.0
0.5
Q2
Company 6
8
1.0
0.2
Company 7
7
1.7
0.5
Company 8
6
1.6
0.3
Company 9
6
1.2
2.2
Q3
Company 10
6
1.0
0.6
Company 11
5
0.8
0.7
Company 12
5
0.6
1.1
Company 13
5
2.2
0.6
70
Q4
Company 14
4
1.2
0.5
Company 15
Company 16 1
3
0.8
0.4
1.0
0.4
Median 6
Median 1.2
Median $0.7
Source: Evaluate Pharma (retrieved April 2021). Peer-set incl top 17 companies by 2020 Rx Sales & Pharma R&D Spend. Includes Vaccines. Includes NMEs and Non-NMEs. Excludes OTC and generics. Includes assets acquired through
business development launched during the period.
* Number of launches (2017-2020) per $1B R&D spend. Average R&D spend 2017-2020; **Median peak year sales from assets launched 2017-2020, PYS between 2017 and 2026
GSK launches: Blenrep (NME), Cabenuva (NME), Rukobia (NME), Shingrix (NME), Zejula (NME), Duvroq (dapro, NME), Krintafel (tafenoquine, NME), Dovato (NDA), Juluca (NDA), Trelegy Ellipta (NDA)
47View entire presentation